Investigational QBECO SSI Therapy Enters Phase 2 Clinical Trial for Crohn’s

Investigational QBECO SSI Therapy Enters Phase 2 Clinical Trial for Crohn’s
Qu Biologics soon will begin recruiting participants for a Phase 2 clinical trial to continue investigating the company’s special platform of immunotherapies, collectively called Site Specific Immunomodulators (SSIs), as a potential therapy for Crohn’s disease. Patients’ enrollment will open soon in five clinical trial sites throughout Canada, first in Vancouver and New Westminster, followed by Vernon, British Columbia and Hamilton, Ontario. More information on the trial and enrollment requirements is available here. The investigational QBECO SSI therapy was designed to restore the body’s normal immune functi
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *